

RESEARCH ARTICLE

Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass

Orfeas Liangos¹, Hocine Tighiouart², Mary C. Perianayagam¹, Alexey Kolyada¹, Won K. Han³, Ron Wald⁴, Joseph V. Bonventre³, and Bertrand L. Jaber¹

¹Division of Nephrology, Caritas St Elizabeth's Medical Center, Boston, MA, USA, ²Biostatistics Research Center, Tufts Medical Center, Boston, MA, USA, ³Renal Division, Brigham and Women's Hospital, Boston, MA, USA, and ⁴Division of Nephrology, St Michael's Hospital, Toronto, Ontario, Canada

Abstract

The purpose of this study was to compare the performance of six candidate urinary biomarkers, kidney injury molecule (KIM)-1, *N*-acetyl- β -D-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin (NGAL), interleukin (IL)-18, cystatin C and α -1 microglobulin, measured 2 h following cardiopulmonary bypass (CPB) for the early detection of acute kidney injury (AKI) in a prospective cohort of patients undergoing cardiac surgery. A total of 103 subjects were enrolled; AKI developed in 13%. Urinary KIM-1 achieved the highest area under the receiver-operator-characteristic curve (AUC 0.78, 95% confidence interval 0.64–0.91), followed by IL-18 and NAG. Only urinary KIM-1 remained independently associated with AKI after adjustment for a preoperative AKI prediction score (Cleveland Clinic Foundation score; $p=0.02$), or CPB perfusion time ($p=0.006$). In this small pilot cohort, KIM-1 performed best as an early biomarker for AKI. Larger studies are needed to explore further the role of biomarkers for early detection of AKI following cardiac surgery.

Keywords: Acute kidney injury; early detection; urinary biomarker; cardiac surgery

Introduction

Acute kidney injury (AKI) is a common complication of cardiac surgery that employs cardiopulmonary bypass (CPB), and is associated with adverse clinical outcomes (Chertow et al. 1998, Bahar et al. 2005). Despite advances in the understanding of its pathophysiology, the clinical management of AKI remains largely supportive. An important reason for this discrepancy is the reliance on serial measurement of serum creatinine for the detection of AKI, which is an imperfect marker in the acute setting. This is related to several factors, including extracellular fluid volume expansion, muscle wasting, and malnutrition, to name a few (Moran & Myers 1985, Star 1998, Bonventre & Weinberg 2003). Animal studies have identified several preventive and treatment strategies for

AKI, which have previously been extensively reviewed (Schrier et al. 2004, Lameire et al. 2005, Bellomo et al. 2005). If instituted early in the disease process, well before serum creatinine changes, these novel treatment strategies may be effective. The lack of early markers of kidney injury remains a limiting step for translating these promising findings to human AKI.

In recent years, several urinary markers of tubular damage have been proposed as more accurate alternatives to serum creatinine for the early detection of AKI following cardiac surgery. These markers include neutrophil gelatinase-associated lipocalin (NGAL) (Mishra et al. 2005, Parikh et al. 2006, Bennett et al. 2008), interleukin (IL)-18 (Parikh et al. 2006), kidney injury molecule (KIM)-1 (Han et al. 2008) and cystatin C (Koyner et al. 2008). Unfortunately, most studies have focused on

Address for Correspondence: Bertrand L. Jaber, Caritas St Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA 02135, USA. Tel.: (617) 562-7832. Fax: (617) 562-7797. E-mail: bertrand.jaber@caritaschristi.org

(Received 16 April 2009; revised 22 May 2009; accepted 26 May 2009)

one or two markers, with variable performance for the early detection of AKI when measured and tested at different time points following CPB.

The objective of this pilot study was to compare the performance characteristics of six of these urinary biomarkers for the early detection of AKI among adults undergoing on-pump cardiac surgery, and to explore whether or not combining such markers enhances their predictive value.

Subjects and methods

Study design and population

This ancillary prospective cohort study was conducted between January 2004 and May 2006 at two tertiary care hospitals located in Boston, Massachusetts, and is part of an ongoing parent study aimed at evaluating genetic risk markers for AKI following cardiac surgery. All consecutive adult subjects (age 18 years or greater) scheduled to undergo on-pump cardiac surgery were eligible for enrolment. Exclusion criteria were age under 18 years, off-pump surgery, pregnancy, long-term or acute dialysis, and organ transplantation within the prior year. Written informed consent was obtained from all study participants or next of kin. The institutional review board of each participating centre approved the study protocol, and the study was conducted in accordance with the ethical standards laid down in the Declaration of Helsinki of 1975, as revised in 1983.

Data collection

Medical records were reviewed prospectively to retrieve hospitalization data, including baseline demographic characteristics, preoperative clinical and laboratory variables, intraoperative variables including surgery electivity and type, CPB perfusion time and aortic cross clamp time, and several postoperative variables including serial serum creatinine measurements. The Cleveland Clinic Foundation (CCF) score (Thakar et al. 2005), an established preoperative AKI risk score was determined for each patient. This score consists of 11 preoperative variables including gender, congestive heart failure, left ventricular ejection fraction, use of intra-aortic balloon counterpulsation, chronic lung disease, insulin-requiring diabetes mellitus, previous cardiac surgery, emergent surgery, valve surgery, procedures other than coronary bypass or valve, and serum creatinine (Thakar et al. 2005). The Acute Physiology and Chronic Health Evaluation (APACHE) II score (Knaus et al. 1985) was determined the first day following surgery. The baseline estimated glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) study four-variable equation (Levey et al. 2000).

Predictor variables

We selected six candidate urinary biomarkers, some of which had previously been tested in isolation, for the early detection of AKI. These included KIM-1, a tubular dedifferentiation marker (Ichimura et al. 1998, Vaidya et al. 2006); *N*-acetyl- β -D-glucosaminidase (NAG), a tubular brush border enzyme (Wellwood et al. 1975, Price 1992); NGAL, an iron-siderophore-binding protein (Mishra et al. 2003); IL-18, a marker of inflammation and potentially a mediator of tubular injury (Parikh et al. 2004); and cystatin C, and α -1 microglobulin, two markers of impaired tubular protein absorption (Herget-Rosenthal et al. 2004). Urinary biomarker measurements obtained 2 h following CPB were used to predict AKI, and compared with the CCF score and CPB perfusion time, two known pre- and intraoperative risk factors for AKI.

Outcome measure

The outcome measure was AKI defined by an increase in serum creatinine by $\geq 50\%$ in the first 72 h following termination of CPB. We chose the 72-h time point instead of the 48-h time point that is currently recommended by the AKI Network definition (Mehta et al. 2007), to account for the haemodilution that occurs during CPB. The latter has previously been described in the literature (Rosner & Okusa 2006). In a sensitivity analysis, *early* AKI was defined as a similar serum creatinine rise in the first 24 h following CPB.

Urine collection, processing and storage

Urine samples were freshly collected prior to surgery, 2, 24 and 48 h following discontinuation of CPB. Samples were kept on ice and centrifuged within 30 min to remove insoluble elements. The supernatant was treated with a protease inhibitor cocktail tablet (Complete Mini; Roche Applied Science, Indianapolis, IN, USA) to prevent biomarker degradation by urinary proteases. Urinary aliquots were stored at -80°C until assayed. Urinary samples were frozen in small aliquots to prevent frequent freeze and thaw cycles during the measurement phase of the study.

Measurement of urinary biomarkers

Urinary KIM-1 was measured using a previously described sandwich enzyme-linked immunosorbent assay (ELISA) (Han et al. 2002). In brief, the wells were incubated with 100 μl of urine at room temperature for 3 h. After four washes with PBS-T, biotinylated AKG 7 antibody was added followed by horseradish peroxidase-conjugated streptavidin, and tetramethyl benzidine as substrate. The KIM-1 lower limit of detection was 0.05 ng ml^{-1} , and the

intra- and interassay coefficients of variation (CV) were 9.4% and 12.9%, respectively. There was no interference of the protease inhibitor cocktail with this assay.

Urinary NAG activity was measured using a previously described colorimetric assay (Boehringer Mannheim GmbH, Mannheim, Germany) (Liangos et al. 2007). The NAG lower limit of detection was 3 mU ml⁻¹, and the inter- and intra-assay CV were 4.3% and 6.0%, respectively.

Urinary NGAL was measured by a human lipocalin-2/NGAL immunoassay (Quantikine®, R&D systems, Minneapolis, MN, USA). According to the manufacturer, this assay does not cross-react with lipocalin-1, matrix metalloproteinase (MMP)-9 or the MMP-9/NGAL complex. The NGAL lower limit of detection was 0.012 pg ml⁻¹, and average inter- and intra-assay CV were 6.5% and 4.0%, respectively. The 2-h post-CPB urinary NGAL values that were undetectable were re-assayed after urinary aliquots were first concentrated using Micron centrifugal filter devices (Millipore Corp., Bedford, MA, USA), according to the manufacturer's instructions.

Urinary IL-18 was measured using a sandwich ELISA (MBL, Naka-ku Nagoya, Japan). The IL-18 lower limit of detection was 3.5 pg ml⁻¹, and the average intra- and inter-assay CV were 5.0% and 7.5%, respectively.

Urinary cystatin C and α -1 microglobulin were measured by a particle-enhanced nephelometric immunoassay using the Behring Nephelometer II System (Dade Behring, Deerfield, IL, USA). The cystatin C lower limit of detection was 0.05 mg l⁻¹, and the average intra- and interassay CV were <2.5% and <3.5%, respectively. The α -1 microglobulin lower limit of detection was 5.6 mg l⁻¹, and the intra- and inter-assay CV were <4.1% and <10.3%, respectively.

All measurements were performed in duplicate by blinded investigators (W.K.H., A.K., M.C.P.) except for NAG, which was performed in single measurements. All time points were evaluated and assay protocols were strictly adhered to. For all the biomarker measurements, outliers, as defined by values that were 2 SD above or below the mean, were re-assayed. All the results were normalized to urinary creatinine values and expressed in the respective biomarker unit per mg of creatinine.

Statistical analysis

Continuous variables were described as means (with SD) or medians (with interquartile range), as appropriate, and categorical variables as percentages. The Wilcoxon rank sum test was used to compare urinary biomarker levels at each time point between patients with and without AKI.

Test performance characteristics for the early detection of AKI were evaluated for each biomarker using a receiver operator characteristic curve (ROC) analysis. In addition, biomarkers with the best area-under-the-ROC

curve (AUC) were combined, biomarkers were compared with the CCF score, and biomarkers with or without the addition of the CCF score and CPB perfusion time were evaluated with the same method. The 95% confidence interval (CI) for the AUC was calculated, and formal statistical testing was performed using the non-parametric method of DeLong et al. (1988).

Optimal cut-off points for early detection of AKI were determined for each biomarker using the Youden index (Youden 1950), based on which sensitivity, specificity, positive and negative predictive values were calculated. The Youden index is calculated by adding sensitivity and specificity and subtracting 1, which identifies the point on the ROC curve that has the maximum vertical distance to the diagonal or chance line. Logistic regression analysis was also used to examine the predictive value of each biomarker for the early detection of AKI, using the 2-h post-CPB time point. For these analyses, all biomarkers were log transformed due to a skewed distribution. The analyses were adjusted for the CCF score or CPB perfusion time. Differences were considered statistically significant at a *p*-value <0.05. All statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).

Results

Characteristics of the cohort

A total of 103 study participants were enrolled, and their characteristics are displayed in Table 1. In brief, mean age was 68 years, 96% were white, 28% were women, preoperative mean left ventricular ejection fraction was 51% and preoperative mean serum creatinine was 1.1 mg dl⁻¹ and baseline estimated GFR 73 ml min⁻¹ × 1.73 m². Serial preoperative serum creatinine values remained stable and none of the enrolled subjects had preoperative AKI. Twenty-eight per cent of patients underwent elective cardiac surgery, the remainder were categorized as urgent but none were emergent. Mean CPB perfusion and aortic cross-clamp times were 111 and 83 min, respectively. In all participants, cardioplegia was achieved, after external aortic cross-clamping, through antegrade and retrograde cold blood diastolic cardioplegic arrest. Cardiac function was regained at the end of CPB either spontaneously by reperfusion with warm, circulating blood or through defibrillation with 20 J. On day 1 following surgery, mean APACHE II score was 9, and postoperative AKI developed in 13 subjects (13%). Serum creatinine profiles throughout the observation time points are shown in Figure 1, indicating similar serum creatinine level prior to CPB as well as excellent and sustained separation between the AKI and non-AKI group following CPB. Preoperative radiocontrast exposure was not associated with development of AKI. Patients who

Table 1. Characteristics of the study cohort.

Variable	All patients (n=103)	No AKI (n=90)	AKI (n=13)	p-Value
<i>Preoperative variables</i>				
Age (years)	68 (11)	67 (12)	73 (9)	0.15
Women, %	28	28	31	1.00
White ethnicity, %	96	96	100	1.00
Hypertension, %	81	81	77	0.71
Diabetes mellitus, %	29	29	31	1.00
Baseline serum creatinine (mg dl ⁻¹)	1.1 (0.3)	1.1 (0.3)	1.1 (0.2)	0.43
Baseline eGFR (ml min ⁻¹ x 1.73 m ²)	73 (18)	73 (18)	68 (15)	0.32
Chronic lung disease, %	21	18	46	0.02
Congestive heart failure, %	23	18	62	0.002
Peripheral vascular disease, %	20	19	31	0.46
Cerebrovascular disease, %	11	10	15	0.63
3-Vessel coronary artery disease, %	52	57	23	0.02
Left main coronary artery disease, %	32	31	39	0.75
Left ventricular ejection fraction, %	51 (12)	52 (12)	47 (16)	0.22
Previous cardiac surgery, %	19	20	15	0.63
Preoperative radiocontrast administration, %	57	57	54	1.00
Preoperative CCF score	2.7 (2.0)	2.5 (1.9)	4.5 (1.2)	< 0.001
<i>Operative variables</i>				
Elective surgery, %	28	28	31	0.82
Valvular surgery, %	40	33	85	0.001
CPB perfusion time (min)	111 (44)	107 (41)	137 (52)	0.05
Aortic cross clamp time (min)	83 (34)	81 (33)	99 (34)	0.07
<i>Postoperative variables</i>				
Assisted mechanical ventilation (h)	31 (111)	22 (95)	90 (181)	0.01
APACHE II score at day 1	9 (4)	8 (3)	15 (5)	< 0.001

Data are shown as mean (SD) or %, p-value by Wilcoxon rank sum or Fisher's exact test, as appropriate; AKI, acute kidney injury; eGFR, estimated glomerular filtration rate calculated by the 4-variable Modification of Diet in Renal Disease equation (Levey et al. 2000); CCF, Cleveland Clinic Foundation; CPB, cardiopulmonary bypass.

developed AKI had a higher preoperative CCF score, a higher prevalence of pre-existing chronic lung disease and congestive heart failure, and were also less likely to have three-vessel coronary artery disease but more likely to undergo valvular surgery. In addition, CPB perfusion time was longer and postoperatively, the AKI group had a higher APACHE II score at day 1 and required prolonged assisted mechanical ventilation. Renal replacement therapy was required in only one case, which also fulfilled the serum creatinine criteria for AKI.




Figure 1. Perioperative median serum creatinine profiles stratified by presence or absence of acute kidney injury (AKI). * $p < 0.001$ vs. no AKI; † $p = 0.004$ vs. no AKI. The AKI group is displayed in grey and the non-AKI group in black. Error bars represent 25th and 75th percentile values. DC, day of hospital discharge.

Perioperative urinary biomarker profiles

Figure 2 displays the perioperative profile of the six urinary biomarkers stratified by AKI. In brief, most urinary biomarkers reached higher median postoperative levels in the AKI group compared with the non-AKI group. However, statistical significance was reached only for KIM-1 and NAG, at the 2-h ($p = 0.001$) and 48-h ($P = 0.02$) time point, respectively. There was also a non-significant trend toward higher urinary IL-18 at the 2-h mark ($p = 0.07$) in the AKI group. In addition, 2-h urinary IL-18 and cystatin C were negatively correlated with postoperative urine output and positively correlated with postoperative total furosemide dose within the first 24 h following CPB. The 2-h urinary KIM-1 was also associated with furosemide dose but not with urine output, whereas α -1 microglobulin was correlated with urine output but not with furosemide dose (data not shown).

Urinary biomarker diagnostic performance

Results of the ROC analysis are displayed in Table 2. In brief, among the urinary biomarkers, the 2-h post-CPB urinary KIM-1 level displayed the highest AUC of 0.78 (95% CI 0.64–0.91; $p < 0.01$), followed by IL-18, NAG and α -1 microglobulin, which were not significant. When combined, the three best performing biomarkers KIM-1, IL-18 and NAG were only marginally and not significantly better than KIM-1 alone (AUC 0.78; 95% CI 0.62–0.94; $p < 0.01$). The AUC of the CPB perfusion time (AUC 0.67; 95% CI 0.52–0.82; $p = 0.02$) was comparable to urinary IL-18, but was lower than that of KIM-1. The CCF score was highly predictive of AKI (AUC 0.83; 95% CI 0.74–0.91, $p < 0.01$) but did not perform significantly better than KIM-1 ($p = 0.54$). When the CPB perfusion time was combined with the 2-h post-CPB urinary KIM-1 level, the performance was not better




Figure 2. Perioperative median urinary biomarker profiles stratified by presence or absence of acute kidney injury (AKI). * $p=0.001$ vs. no AKI; † $p=0.02$ vs. no AKI. The AKI group is displayed in grey and the non-AKI group in black. Error bars represent 25th and 75th percentile values. KIM, kidney injury molecule; NAG, *N*-acetyl- β -D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; IL, interleukin.

than KIM-1 alone ($p=0.79$). When the CCF score was combined with KIM-1, the performance improved substantially over that of KIM-1 alone, reaching statistical significance ($p=0.02$).

Table 3 displays the optimal biomarker cut-off values and their corresponding sensitivities, specificities, positive and negative predictive values at the 2-h post-CPB time point. At a cut-off value of 0.42 ng mg^{-1} , urinary KIM-1 displayed the best sensitivity and specificity of 92% and 58%.

In a sensitivity analysis restricted to *early* AKI, as defined by a steeper rise in serum creatinine of equal

or greater than 50% within the first 24 h, the diagnostic performance of the 2-h post-CPB urinary KIM-1 strengthened with an AUC of 0.91 (95% CI 0.80–1.00; $p<0.01$). Using the urinary KIM-1 optimal cut-off value of 0.95 ng mg^{-1} , as determined by the Youden index, the corresponding sensitivity and specificity of this biomarker for detection of *early* AKI improved to 100% and 76%, respectively. Of note, the diagnostic performance of the other five urinary biomarkers or of the CCF score, as measured by the AUC, did not significantly change when tested in this sensitivity analysis.

Logistic regression analyses

Results of the logistic regression analyses are displayed in Table 4. On univariate analysis, each two-fold increase in 2-h post-CPB urinary KIM-1 and IL-18 increased the odds of developing AKI by 1.96-fold ($p < 0.01$), and 1.38-fold ($p = 0.04$), respectively. The other urinary biomarkers were not significantly associated with development of AKI. Following adjustment for either the CCF score or the CPB perfusion time, only KIM-1 remained independently associated with development of AKI (Table 4).

Discussion

In this prospective pilot study of adults undergoing on-pump cardiac surgery, we compared the predictive value of six candidate urinary biomarkers measured 2 h following CPB, for the early detection of AKI. Urinary KIM-1 displayed the best diagnostic performance. A type 1 transmembrane protein, KIM-1 is a tubular dedifferentiation marker that is upregulated in proximal tubules following ischaemic and toxic injury, and is detected in human AKI (Ichimura et al. 1998, Han et al. 2002). Shedding of its

ectodomain results in the appearance of a 90-kDa, soluble form of KIM-1 in the urine (Bailly et al. 2002), which has been proposed to be sensitive and highly specific for the detection of AKI in humans (Han et al. 2002, 2008).

Other urinary biomarkers tested in the present study performed less well, notably urinary NGAL, which had previously been shown to have an excellent diagnostic performance, particularly among children undergoing cardiac surgery (Mishra et al. 2005, Parikh et al. 2006). More recent studies on the use of urinary NGAL in an adult cardiac surgical population have been less impressive (Wagener et al. 2006, 2008). The apparent variability in the discriminatory value of urinary biomarkers between children and adults might in part be due to differences in patient characteristics including the burden of comorbidities in adults undergoing cardiac surgery, especially cardiovascular and chronic kidney disease. Other reasons for discrepancies amongst the urinary NGAL diagnostic studies might be related to differences in the measurement methods employed, including western blots and research-based commercially available ELISA kits, as well as differences in storage times of urine samples.

IL-18 has previously been shown to mediate ischaemic injury through activation of apoptosis in renal tubular epithelial cells (Melnikov et al. 2001, 2002). Urinary IL-18 performed better in our adult cohort than in a previously reported paediatric cohort undergoing on-pump cardiac surgery, despite similar perioperative urinary levels, and a similarly adopted AKI definition (Parikh et al. 2006). Urinary cystatin C and α -1 microglobulin, two tubular protein reabsorption markers that have previously been tested for prediction of dialysis requirement among patients with established non-oliguric AKI (Herget-Rosenthal et al. 2004), did not perform well enough in our study to serve as reliable markers for early detection of AKI. These results contrast with a recent report demonstrating that urinary cystatin C, when measured 6 h after CPB, is most useful for predicting AKI (Koyner et al. 2008).

Lastly, urinary NAG, a proximal tubular epithelial cell glycosidase that is considered a *legacy* biomarker for detection of kidney injury (Wellwood et al. 1975) has

Table 2. Area-under-the-receiver-operator-characteristic curve (AUC) of the 2-h post-cardiopulmonary bypass (CPB) urinary biomarker levels for early detection of acute kidney injury.

Predictor variable	AUC	95% CI
KIM-1	0.78	0.64–0.91
NAG	0.62	0.41–0.83
NGAL	0.50	0.33–0.68
IL-18	0.66	0.49–0.83
Cystatin C	0.50	0.27–0.72
α -1 Microglobulin	0.62	0.47–0.76
KIM-1, NAG and IL-18	0.78	0.62–0.94
KIM-1 and CPB perfusion time	0.78	0.64–0.94
KIM-1 and preoperative CCF score	0.88	0.81–0.96

CI, confidence interval; CPB, cardiopulmonary bypass; CCF, Cleveland Clinic Foundation; KIM, kidney injury molecule; NAG, *N*-acetyl- β -D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; IL, interleukin.

Table 3. Urinary biomarker test characteristics based on optimal cut-off value for the 2-h post-cardiopulmonary bypass (CPB) time point for detection of acute kidney injury.

Predictor variable	Optimal cut-off point ^a	Sensitivity(%)	Specificity(%)	Positive predictive value (%)	Negative predictive value (%)
KIM-1 (ng mg ⁻¹)	0.42	92	58	24	98
NAG (mU mg ⁻¹)	66	50	79	26	91
NGAL (ng mg ⁻¹)	166	67	11	15	90
IL-18 (pg mg ⁻¹)	92	75	66	25	95
Cystatin C (ng mg ⁻¹)	192	42	86	31	91
α -1 Microglobulin (μ g mg ⁻¹)	115	75	58	21	94

^aThe optimal cut-off point value was generated using the Youden index.

KIM, kidney injury molecule; NAG, *N*-acetyl- β -D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; IL, interleukin.

Table 4. Association of 2-h post-cardiopulmonary bypass (CPB) urinary biomarker level with development of acute kidney injury.

Predictor variable	OR	95% CI	p-Value
<i>Unadjusted</i>			
KIM-1	1.96	1.26–3.05	0.003
NAG	1.40	0.96–2.06	0.08
NGAL	1.01	0.87–1.16	0.93
IL-18	1.38	1.02–1.88	0.04
Cystatin C	1.02	0.75–1.39	0.88
α -1 Microglobulin	1.33	0.88–2.01	0.17
<i>Adjusted for preoperative CCF score</i>			
KIM-1	1.69	1.10–2.59	0.02
NAG	1.25	0.83–1.90	0.29
IL-18	1.29	0.92–1.82	0.14
<i>Adjusted for intraoperative CPB perfusion time</i>			
KIM-1	1.86	1.20–2.89	0.006
NAG	1.27	0.84–1.91	0.25
IL-18	1.28	0.91–1.78	0.15

Logistic regression models were generated to indicate odds ratios (OR) per doubling in the urinary biomarker level.

CI, confidence interval; KIM, kidney injury molecule; NAG, *N*-acetyl- β -D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; IL, interleukin; CCF, Cleveland Clinic Foundation.

previously been shown to increase in response to cardiac surgery (Gormley et al. 2000), and is a good predictor of adverse outcomes in patients with established AKI (Liangos et al. 2007). Unfortunately, in the present study, similarly to four of the markers, the utility of NAG as an early detection marker was limited, although it strengthened over the observation time interval and displayed a fair performance 48 h post-CPB (data not shown).

There are several strengths and limitations of this study that should be noted. To our knowledge, this is the first study to compare the prediction value of six candidate urinary biomarkers for the early detection of AKI. Although our study cohort was relatively small, the sample size is consistent with the majority of the previously published reports of prospective studies of urinary AKI biomarkers (Mishra et al. 2005, Wagener et al. 2006, Parikh et al. 2006). As our study was ancillary to a parent study not originally designed to examine the predictive value of urinary biomarkers for early detection of AKI, only a single early post-CPB time point was available for evaluation. This is an important shortcoming and represents a limitation of our study and contrasts with previous studies that performed more frequent measurements in the first 12 h following surgery and found better predictive performance of markers at later time points. On the other hand, focusing on a very early postoperative period is relevant, as potentially successful therapeutic interventions for AKI are likely to be beneficial if instituted in this very early postoperative period.

With a total number of 103 patients included in the study and an AKI frequency of 13%, the study is underpowered to provide definitive conclusions on

urine biomarker performance. Nevertheless, one of the biomarkers, KIM-1, performed fairly well, even after adjustment for important preoperative variables, and appeared better in direct comparison with the other markers tested. In the present study, we normalized the urinary biomarker levels to urinary creatinine in order to account for differences in relative amounts of water extracted along the nephron. Although the results were attenuated somewhat when absolute urinary biomarker values were used in the analysis, urinary KIM-1 maintained its statistical significance as well as its superiority compared with the other markers without normalization for urinary creatinine (data not shown). The clinical diagnosis of AKI rests on acute changes in serum creatinine, which can be affected by haemodynamic alterations of GFR in the acute postoperative period, and thereby attenuate the relationship of urinary biomarker levels and subsequent change in serum creatinine. Potential discrepancies between the presence of kidney injury and changes in serum creatinine are further underscored in our study by the association of urinary biomarkers not predictive of serum creatinine changes, with decreased urine output and requirement for diuretic therapy, both indicators of kidney dysfunction or injury. Nevertheless, serum creatinine remains an accepted and most widely used method for the detection of AKI.

We used a clinical definition that has been widely utilized in previous reports (Mishra et al. 2005, Wagener et al. 2006, Parikh et al. 2006, Bennett et al. 2008). Although patient population heterogeneity could be an important cause for discrepancies between our results and those published by others in the literature, the current lack of a common validated measurement platform for the tested biomarkers with resulting variable measurement methods, and differences in the definition of AKI are also likely to introduce an additional element of heterogeneity when comparing results across studies. We can only speculate as to whether or not these methodological heterogeneities might explain the differences in results observed for some of the tested urinary biomarkers between this and other previously published studies. We attempted to optimize the urinary samples through removal of cellular elements, addition of protease inhibitors and storage at -80°C to minimize biomarker degradation, concentration of diluted samples using centrifugal filter devices, and normalizing the biomarker values to urinary creatinine. In addition, all urinary samples were frozen in multiple separate small aliquots to prevent frequent freeze and thaw cycles and subsequent biomarker degradation.

The performance of the CCF score in our cohort merits further discussion. This clinical score predicted AKI very well and although it lacked statistical superiority over KIM-1, it could be viewed as a useful substitute for a biomarker-based method. Its advantages are early

availability and low cost; however, its disadvantages include the need to collect 11 variables and calculating a score, which could be cumbersome. In addition, the score is specific for preoperative cardiac surgical patients, whereas biomarkers have the potential to be used in other clinical settings, although this cannot be concluded from the present study.

In conclusion, in the present pilot study, we tested six distinct urinary biomarker candidates for their performance characteristics as early detection markers for AKI among adults undergoing on-pump cardiac surgery. When measured 2 h post-CPB, urinary KIM-1 displayed the best diagnostic performance for detection of AKI, and was followed by IL-18. Urinary NGAL, cystatin C, α -1 microglobulin, and NAG also did not adequately predict AKI at the 2-h post-CPB time point. A large multicentre cohort study of adults undergoing on-pump cardiac surgery is required to identify the best single or combination of biomarkers, using numerous time points to further refine the optimal timing for early detection of AKI.

Acknowledgements

This study was supported by grants from the Norman Coplon Research Program of Satellite Healthcare, Inc. (to B.L.J.), the American Heart Association (to O.L.), and the Earl P. Charlton Research Program of Tufts University School of Medicine (to O.L.). O.L. is supported by a grant from the American Heart Association (AHA no. 0535367N). B.L.J. is supported by grants from the National Institutes of Health (DK065102 and DK077751). J.V.B. is supported by grants from the National Institutes of Health (DK 39773, DK 074099, DK 072381). W.K.H. is supported by a grant from the National Institutes of Health (DK64075). The authors thank members of the Divisions of Cardio-thoracic Surgery at each participating institution, and Noreen Dolan, RN and Robert W. MacKinnon RN for assistance with enrolment of study participants, and Mary Lou Ganzer, PhD (Siemens Healthcare Diagnostics, Deerfield, IL) for loaning the Behring Nephelometer II System to the Kidney & Dialysis Research Laboratory of Caritas St Elizabeth's Medical Center, and for providing expert technical advice. This work was presented in part at the 40th Annual Meeting of the American Society of Nephrology, San Francisco, CA, USA, 31 October to 5 November, 2007.

Declaration of interests: The authors alone are responsible for the content and writing of the paper. J.V.B. is a co-inventor on KIM-1 patents (patent numbers 6,664,385 and 7,179,901) that are licensed to Johnson and Johnson.

References

- Bahar I, Akgul A, Ozatik MA, Vural KM, Demirbag AE, Boran M, Tasdemir O. (2005). Acute renal failure following open heart surgery: risk factors and prognosis. *Perfusion* 20:317–22.
- Bailly V, Zhang Z, Meier W, Cate R, Sanicola M, Bonventre JV. (2002). Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. *J Biol Chem* 277:39739–48.
- Bellomo R, Bonventre J, Macias W, Pinsky M. (2005). Management of early acute renal failure: focus on post-injury prevention. *Curr Opin Crit Care* 11:542–7.
- Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, Syed H, Ali S, Barasch J, Devarajan P. (2008). Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. *Clin J Am Soc Nephrol* 3:665–73.
- Bonventre J, Weinberg J. (2003). Recent advances in the pathophysiology of ischemic acute renal failure. *J Am Soc Nephrol* 14:2199–210.
- Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. (1998). Independent association between acute renal failure and mortality following cardiac surgery. *Am J Med* 104:343–8.
- DeLong ER, DeLong DM, Clarke-Pearson DL. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 44:837–45.
- Gormley SM, McBride WT, Armstrong MA, Young IS, McClean E, MacGowan SW, Campalani G, McMurray TJ. (2000). Plasma and urinary cytokine homeostasis and renal dysfunction during cardiac surgery. *Anesthesiology* 93:1210–16; discussion 5A.
- Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. (2002). Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. *Kidney Int* 62:237–44.
- Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P, Bonventre JV. (2008). Urinary biomarkers in the early diagnosis of acute kidney injury. *Kidney Int* 73:863–9.
- Herget-Rosenthal S, Poppen D, Husing J, Marggraf G, Pietruck F, Jakob HG, Philipp T, Kribben A. (2004). Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. *Clin Chem* 50:552–8.
- Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M. (1998). Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. *J Biol Chem* 273:4135–42.
- Knaus WA, Draper EA, Wagner DP, Zimmerman JE. (1985). APACHE II: a severity of disease classification system. *Crit Care Med* 13:818–29.
- Koyner JL, Bennett MR, Worcester EM, Ma Q, Raman J, Jeevanam V, Kasza KE, Connor ME, Konczal DJ, Trevino S, Devarajan P, Murray PT. (2008). Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. *Kidney Int* 74:1059–69.
- Lameire N, Van Biesen W, Vanholder R. (2005). Acute renal failure. *Lancet* 365:417–30.
- Levey AS, Greene T, Kusek JW, Beck GJ. (2000). A Simplified equation to predict glomerular filtration rate from serum creatinine. *J Am Soc Nephrol* 11:155A.
- Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H, Mackinnon RW, Li L, Balakrishnan VS, Pereira BJ, Bonventre JV, Jaber BL. (2007). Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. *J Am Soc Nephrol* 18:904–12.
- Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. (2007). Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 11:R31.
- Melnikov VY, Ecker T, Fantuzzi G, Siegmund B, Lucia MS, Dinarello CA, Schrier R, W, Edelstein CL. (2001). Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. *J Clin Invest* 107:1145–52.
- Melnikov VY, Faubel S, Siegmund B, Lucia MS, Ljubanovic D, Edelstein CL. (2002). Neutrophil-independent mechanisms of

- caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. *J Clin Invest* 110:1083-91.
- Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. (2005). Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. *Lancet* 365:1231-8.
- Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. (2003). Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. *J Am Soc Nephrol* 14:2534-43.
- Moran SM, Myers BD. (1985). Course of acute renal failure studied by a model of creatinine kinetics. *Kidney Int* 27:928-37.
- Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. (2004). Urinary interleukin-18 is a marker of human acute tubular necrosis. *Am J Kidney Dis* 43:405-14.
- Parikh CR, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C, Dent C, Devarajan P, Edelstein CL. (2006). Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. *Kidney Int* 70:199-203.
- Price RG. (1992). The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. *Clin Nephrol* 38 (Suppl. 1): S14-19.
- Rosner MH, Okusa MD. (2006). Acute kidney injury associated with cardiac surgery. *Clin J Am Soc Nephrol* 1:19-32.
- Schrier RW, Wang W, Poole B, Mitra A. (2004). Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. *J Clin Invest* 114:5-14.
- Star RA. (1998). Treatment of acute renal failure. *Kidney Int* 54:1817-31.
- Thakar CV, Arrigain S, Worley S, Yared JP, Paganini EP. (2005). A clinical score to predict acute renal failure after cardiac surgery. *J Am Soc Nephrol* 16:162-8.
- Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. (2006). Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. *Am J Physiol Renal Physiol* 290:F517-29.
- Wagener G, Gubitosa G, Wang S, Borregaard N, Kim M, Lee HT. (2008). Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. *Am J Kidney Dis* 52:425-33.
- Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, Lee HT. (2006). Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. *Anesthesiology* 105:485-91.
- Wellwood JM, Ellis BG, Price RG, Hammond K, Thompson AE, Jones NE. (1975). Urinary N-acetyl-beta-D-glucosaminidase activities in patients with renal disease. *BM J* 3:408-11.
- Youden WJ. (1950). Index for rating diagnostic tests. *Cancer* 3:32-5.